Doxercalciferol Before Surgery in Treating Localized Prostate Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically or cytologically confirmed localized adenocarcinoma of the prostate
• •Candidate for prostatectomy
• •PATIENT CHARACTERISTICS:
• •Age:
• •21 and over
• •Performance status:
• •Not specified
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •WBC at least 4,000/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hepatic:
• •Bilirubin no greater than 1.4 mg/dL
• •AST no greater than 3 times normal
• •Renal:
• •Creatinine no greater than 2.0 mg/dL
• •Calcium no greater than 10.2 mg/dL
• •No idiopathic urinary calcium stone disease
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •Not specified
• •Endocrine therapy:
• •No prior hormonal therapy for prostate cancer
• •No concurrent hormonal therapy, including luteinizing hormone-releasing hormone agonists, antiandrogens, glucocorticoids, ketoconazole, finasteride, diethylstilbestrol, or progestins
• •Radiotherapy:
• •No prior brachytherapy or external beam radiotherapy for prostate cancer
• •Surgery:
• •See Disease Characteristics
• •Other:
• •At least 7 days since prior vitamin D therapy or calcium supplements
• •No other concurrent vitamin D analogues or calcium supplements
• •No concurrent magnesium-containing antacids
• •No concurrent thiazide-containing diuretics
• •No concurrent phenytoin, phenobarbital, glutethimide, digoxin, or digitalis